← Ablatotech Vitals
Orthopedics EvidenceDigest

Current Evidence on the Use of Extracorporeal Shock Wave Therapy for Chronic Tendinopathy

Orthopedics · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 5, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Extracorporeal shock wave therapy (ESWT) is a non-invasive treatment modality showing moderate efficacy in reducing pain and improving function in patients with chronic tendinopathies, particularly Achilles and plantar fasciitis. Evidence supports its use as an adjunct or alternative to conventional therapies, with a favorable safety profile. However, heterogeneity in treatment protocols and patient populations limits definitive conclusions. ESWT may be most beneficial in midportion Achilles tendinopathy and non-calcific supraspinatus tendinopathy, but optimal dosing and long-term outcomes require further clarification (De la Corte-Rodríguez et al., 2023; Feeney et al., 2022).

Clinical bottom line

Extracorporeal shock wave therapy (ESWT) is a non-invasive treatment modality showing moderate efficacy in reducing pain and improving function in patients with chronic tendinopathies, particularly Achilles and plantar fasciitis. Evidence supports its use as an adjunct or alternative to conventional therapies, with a favorable safety profile. However, heterogeneity in treatment protocols and patient populations limits definitive conclusions. ESWT may be most beneficial in midportion Achilles tendinopathy and non-calcific supraspinatus tendinopathy, but optimal dosing and long-term outcomes require further clarification (De la Corte-Rodríguez et al., 2023; Feeney et al., 2022).

What the evidence shows

De la Corte-Rodríguez et al. (2023) provide a recent narrative review summarizing ESWT’s mechanisms, including stimulation of neovascularization, modulation of inflammation, and promotion of tissue regeneration. They highlight clinical studies demonstrating pain reduction and functional improvement across various musculoskeletal pain syndromes, including tendinopathies.

Feeney et al. (2022) conducted a systematic review focusing on midportion Achilles tendinopathy, reporting that ESWT significantly improves pain scores and patient-reported outcomes compared to placebo or conservative management. The authors note variability in shock wave energy levels and treatment frequency across studies.

Gerdesmeyer et al. (2015) offer a landmark review emphasizing ESWT’s efficacy in chronic Achilles tendinopathy, with sustained benefits up to 12 months post-treatment. They also discuss the distinction between focused and radial shock waves and their respective clinical applications.

Galasso et al. (2012) investigated ESWT in chronic non-calcific supraspinatus tendinopathy, demonstrating improved pain and shoulder function, suggesting ESWT as a viable option when conservative measures fail.

Pan et al. (2025) review emerging evidence supporting ESWT’s role in Achilles tendinopathy, underscoring advances in treatment protocols and patient selection to optimize outcomes.

Furia (2007) provides foundational insights into ESWT for plantar fasciitis and Achilles tendinopathy, reporting favorable safety and efficacy profiles, which remain relevant given consistent findings in subsequent studies.

Caveats and uncertainty

Heterogeneity in ESWT devices, energy settings, and treatment schedules complicates standardization.

Placebo effects and natural disease course may confound interpretation of some clinical trials.

Limited data exist on long-term durability beyond one year.

Comparative effectiveness versus other interventions such as eccentric loading or injections remains underexplored.

Patient selection criteria predictive of response are not well-defined.

How this may change practice

ESWT can be considered as a treatment option for patients with chronic tendinopathy refractory to first-line conservative therapies.

Clinicians should tailor ESWT protocols based on tendinopathy location, chronicity, and patient tolerance.

Integration of ESWT into multimodal rehabilitation programs may enhance functional recovery.

Awareness of device-specific parameters and training is essential to optimize safety and efficacy.

Further research and consensus guidelines will aid in refining indications and standardizing treatment protocols.


References

  1. De la Corte-Rodríguez H, et al. Extracorporeal Shock Wave Therapy for the Treatment of Musculoskeletal Pain: A Narrative Review. Healthcare (Basel). 2023; DOI:10.3390/healthcare11212830
  2. Feeney KM, et al. The Effectiveness of Extracorporeal Shockwave Therapy for Midportion Achilles Tendinopathy: A Systematic Review. Cureus. 2022; DOI:10.7759/cureus.26960
  3. Gerdesmeyer L, et al. Current evidence of extracorporeal shock wave therapy in chronic Achilles tendinopathy. Int J Surg. 2015; DOI:10.1016/j.ijsu.2015.07.718
  4. Galasso O, et al. Extracorporeal shock wave therapy for the treatment of chronic non-calcific tendinopathy of the supraspinatus. ISRCTN. 2012; DOI:10.1186/isrctn41236511
  5. Pan N, et al. Achilles Tendinopathy Treatment with a Focus on Extracorporeal Shock Wave Therapy. Proc 1st Int Conf Biomed Eng Food Sci. 2025; DOI:10.5220/0014494800004933
  6. Furia JP. Extracorporeal shock wave therapy in the treatment of chronic plantar fasciitis and Achilles tendinopathy. Curr Opin Orthop. 2007; DOI:10.1097/bco.0b013e328013e594

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team